ARTICLE | Clinical News
ATL-1251 renzapride: AZM will start this quarter an 8-week placebo-controlled European Phase IIb study of ATL-1251 given once daily in 160 IBS patients with mix
February 4, 2002 8:00 AM UTC
Alizyme plc (LSE:AZM), Cambridge, U.K. Product: ATL-1251 renzapride Business: Gastrointestinal Therapeutic category: Receptor agonist Target: Serotonin 5-HT4 receptor and 5-HT3 receptor Description: ...